Idenix Hepatitis C Agent To Enter Phase III In Early 2006
Idenix expects to finalize its valopicitabine Phase III trial protocol by March 2006 for treatment-refractory hepatitis C patients and begin enrollment shortly thereafter
Idenix expects to finalize its valopicitabine Phase III trial protocol by March 2006 for treatment-refractory hepatitis C patients and begin enrollment shortly thereafter